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ABSTRACT
Background Prostate cancer (PCa) is a major 
health problem worldwide. Taxol derivatives- based 
chemotherapies or immunotherapies are usually proposed 
depending on the symptomatic status of the patient. In the 
case of immunotherapy, tumors develop robust immune 
escape mechanisms that abolish any protective response, 
and to date why prostate cancer is one of the most 
resistant diseases remains unresolved.
Methods By using a combination of clinical data to study 
the transcriptome of metastasis samples from patients 
with castration- refractory prostate cancer, and state of the 
art cellular and molecular biology assays in samples from 
tumor- bearing mice that have been submitted to surgical 
resection of the tumor before receiving a vaccination, 
we answered several essential questions in the field of 
immunotherapy for prostate cancer. We also used two 
different methods to inhibit the expression of galectin-3 
(Gal-3) in tumor cells: a stable RNA interference method 
to control the expression of this galectin efficiently only in 
tumor cells, and low and non- cytotoxic doses of docetaxel 
to easily transfer our findings to clinical settings.
Results Herein, we show for the first time that Gal-3 
expressed by prostate tumor cells is the main immune 
checkpoint responsible for the failure of vaccine- based 
immunotherapy. Our results show that low and non- 
cytotoxic doses of docetaxel lead to the inhibition of Gal-3 
expression in PCa cells as well as in clinical samples 
of patients with metastatic and castration- resistant 
PCa promoting a Th1 response. We thus optimized a 
prostate cancer animal model that undergoes surgical 
resection of the tumor to mimic prostatectomy usually 
performed in patients. Importantly, using Gal-3- knocked 
down- PCa cells or low and non- cytotoxic doses of taxane 
before vaccination, we were able to highly control tumor 
recurrence through a direct impact on the proliferation and 
infiltration of CD8+ cytotoxic T.
Conclusions Thus, Gal-3 expression by PCa cells is 
a crucial inhibitor for the success of immunotherapy, 
and low doses of docetaxel with non- cytotoxic effect on 
leukocyte survival could be used before immunotherapy 
for all patients with PCa to reduce the expression of this 
critical negative immune checkpoint, pre- conditioning the 
tumor- microenvironment to activate an antitumor immune 
response and promote tumor- free outcome.
BACKGROUND
Prostate cancer (PCa) is responsible for 
suffering and death worldwide (International 
Agency for Research on Cancer, WHO).1 
Early diagnosis and rapid treatment play crit-
ical roles in patient outcome. While initial 
phases with localized and castration- sensitive 
PCa are curable, those with metastatic and 
castration- resistant PCa (mCRPC) are not. At 
this stage, the primary treatment option for 
symptomatic patients is chemotherapy with 
Taxol- derived molecules such as docetaxel. 
However, 50% of the patients develop chemo-
therapy resistance, and few other therapeutics 
are available.2 It is, therefore, essential to eval-
uate alternative approaches to prevent tumor 
spreading and progression to advanced 
stages of this disease. In this scenario, immu-
notherapy represents an exciting option to 
induce an antitumor response by targeting 
the patient’s immune system directly.3
Immunotherapy is an attractive therapeutic 
strategy for PCa since the immune system 
does not ignore tumor cells, as evidenced 
by the presence of lymphocyte infiltration in 
prostate tumors.4 These infiltrates are also 
characterized by high levels of regulatory T 
cells (TReg).5–7 Recent clinical data provide 
clear evidence of antigenic determinants 
expressed in various types of human tumors 
that could be targeted by autologous T cells, 
and optimization of such reactivity could lead 
to cancer regression.8–10 Sipuleucel- T, the 
first Food and Drug Administration (FDA)- 
approved antigen- specific immunotherapy 
for cancer treatment, is a personalized vaccine 
based on autologous dendritic cells (DC) that 
are supposed to activate PAP- specific CD4+ 
and CD8+ T cells in treated patients with 
PCa.11 Sipuleucel- T is only used for asymp-
tomatic patients with mCRPC and induces 
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a 4.1- month improvement in median survival. Further-
more, analysis of the 3- year survival rate demonstrated an 
8.7% improvement in patients treated with Sipuleucel- T 
compared with the placebo group but without adequate 
control of disease progression.12
In contrast, GVAX, an allogenic PCa tumor vaccine, 
failed to demonstrate overall efficiency when compared 
with docetaxel as the reference therapy. Altogether, the 
low efficiency of immunotherapies13 demonstrates that 
prostate tumor cells create a particular microenviron-
ment to evade immune attacks. In this respect, encour-
aging results have been obtained in clinical trials based 
on over- riding T cell tolerance.14–18
During the last decade, the scientific community demon-
strated the involvement of protein- glycan interactions in 
shaping a tumor- associated immune- suppressive micro-
environment19 through multiple mechanisms.20–27 While 
these functions of glycans seem unequivocally described 
and proven in several experimental settings, the recogni-
tion of the glycophenotype by lectins, in particular galec-
tins (Gals), is likely an essential means of tumor- immune 
tolerance. Interestingly, Gals have been implicated in 
several situations of immune regulation, with major roles 
in shaping T cell function in different experimental 
settings and promoting tumor immune tolerance.28 In 
particular, much attention has been focused on galectin-1 
(Gal-1), a member of this family with higher expression 
levels in PCa and the only galectin whose expression is 
upregulated during disease progression. Gal-1 seems to 
have a significant effect on neovascularization in PCa.29
In contrast, the downregulation of full- length Gal-3 
observed in patients matches neither with the definition 
of Gal-3 as a marker of PCa tumor cell aggressiveness nor 
with a poor prognosis marker for patients with PCa that 
were previously demonstrated.30–32 Gal-3 is ubiquitously 
expressed in various mammalian tissues, localized both 
in cytoplasm and nuclei33 and able to be secreted to 
the extracellular medium, where it interacts with many 
glycoproteins and glycolipids in the cell membrane. 
In the nuclei, it has been proven to participate in the 
modulation of cell survival, DNA damage response,34 
and messenger RNA splicing.35 36 It has also been shown 
to participate in numerous molecular pathways related 
to the development of cancers, such as activation of the 
K- ras/MEK pathway37 and the Wnt, Notch, and EGFR/
FGFR pathways, closely related to cancer stemness.38 
However, because Gal-3 controls the functions of a variety 
of antitumor immune cells,28 39–44 we decided to further 
investigate its role in antitumor immune responses. To 
rapidly transfer our results to clinics, we paid special 
attention to conditions where a chemotherapy treatment 
is associated with vaccination since results from clinical 
trials have shown that docetaxel- based chemotherapy 
could promote the effectiveness of immunotherapy in a 
variety of cancers45–50 as well as in patients with PCa.51 52 
To date, the mechanism of this synergic effect of the 
combinatory therapy protocol remains unclear. Alto-
gether, these clinical results reveal that much needs to be 
understood to improve the efficiency of immunotherapy 
in PCa.
Herein, our results highlight that prostate tumors 
recover high expression of Gal-3 at metastatic stages of 
the disease, and that Gal-3 expressed by PCa cells is the 
main negative checkpoint responsible for the immuno-
therapy failure in patients. We also show that treatment 
with low and non- toxic doses of docetaxel (LDD) highly 
downregulates this new negative immune checkpoint. 
Finally, we propose a simple immunotherapy protocol 
in which a treatment of PCa cell lines or mice- bearing 
tumors with LDD right after primary tumor resection 
and before immunotherapy promotes the effectiveness 
of an anti- PCa therapeutic vaccine through the precondi-
tioning downregulation of tumor- expressing Gal-3. Such 
a strategy allows the activation and expansion of anti-
tumor CD8+ cytotoxic T cells to control tumor recurrence 
effectively. These findings could be rapidly transferred to 
clinical protocols for all patients with PCa.
MATERIALS AND METHODS
Cells and animals
Murine PCa cell line TRAMP- C1 (TC1; obtained from 
ATCC in 2009) was cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM; Invitrogen), 10% heat- 
inactivated fetal bovine serum (FBS) (Gibco), antibiotics 
(penicillin 1 U/mL, streptomycin 1 µg/mL, amphoter-
icin 2.5 ng/mL) and insulin (5 µg/mL). Cell morphology 
was routinely evaluated, and cells were periodically exam-
ined for androgen sensitivity (MTT assay) and myco-
plasma contamination (PCR and DAPI staining followed 
by fluorescent microscopy). For the in vivo assays, 
6- week- old male wild- type C57BL/6 mice were obtained 
from FCEyN- UBA (Buenos Aires, Argentina), 6- week- old 
nude Foxn1nu C57BL/6 mice were obtained from The 
National University of La Plata (La Plata, Argentina) and 
maintained in accordance with the Institutional Animal 
Care and Use Committee guidelines (IAUCC protocol 
#2016–038, FCEyN, Buenos Aires, Argentina) and Animal 
procedures complied with the Guidelines for the Welfare 
of Animals in Experimental neoplasia (UK). Docetaxel 
treatment (0.83 mg/kg/mouse: a LDD did not present 
cytotoxic activity neither against TC1 tumor growth nor 
lymph node or blood cell viability (data not shown)) was 
performed for 2 weeks and once a week by intraperito-
neal (IP) injections.
Lentivirus vector production and transduction of cells
Lentivirus production and transduction of TC1 cells were 
performed as previously described.29 After 1 week, trans-
duced cells (GFP+) were purified by cell sorting using a 
FACSAria II cytometer (BD Bioscience). Purification of 
the transduced cells was carried out if GFP+ cells did not 
exceed 20%, in order to minimize the number of viral 
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Real-time RT-PCR
Transcriptional profile of galectins was analyzed in all cell 
lines at log phase of growth. RNA purification, reverse 
transcription reaction, quantitative PCR conditions and 
data analysis were performed as previously described.29 
36B4 was used as an internal reference gene.53 Primers 
sequences are listed in.29 Equivalent amounts of RNA were 
tested to rule out residual genomic DNA contamination.
High-throughput cDNA analysis of mCRPC clinical samples
We browsed the clinical sample data from.54 These data 
were obtained from a cohort of patients with PCa at a 
different stage of the disease. We selected 35 patients with 
mCRPC to study their gene expression profiles, including 
three untreated patients with mCRPC as the reference 
population, and 32 patients treated with taxane- based 
chemotherapy. Gene expression levels were calculated as 
the relative expression of an individual gene to the gene’s 
expression level in a reference population. The study 
approval and patients consent were included in the orig-
inal publication.54
Immunoblotting, immunohistochemistry, and flow cytometry 
analysis
Immunoblotting and immunohistochemistry and 
flow cytometry analysis were performed as previously 
described,29 55 and primary antibodies are listed in online 
supplemental table 3.
Cell growth analysis
Cell growth was determined by numbering viable cells at 
regular intervals of time. Initially, 5000 cells were seeded 
in 96- well plates in complete culture medium in tripli-
cate for each culture condition. Treatment with indicated 
doses of docetaxel (kindly gift from Roffo hospital, CABA, 
Argentina) was performed on day 1 post- cell plating. The 
cells were trypsinized on day 3 post- treatment and counted 
in a Neubauer chamber in the presence of trypan blue to 
discriminate viable from dead cells.
Tumor growth analysis
TC1- shCtrl or TC1- shGal-3 (2×106 tumor cells/mouse in 
50% v/v Matrigel, BD Biosciences) were subcutaneously 
injected into 6 to 8 week- old male wild- type or Foxn1nu 
nude mice in the right flank and measured as previously 
described.53 When the tumor reached an approximate 
volume of 1.5 cm3, animals were sacrificed and tumors 
were fixed with 4% formaldehyde in phosphate- buffered 
saline (PBS) and then paraffin sections (5 µm thick) were 
processed and stained with modified Masson trichrome 
(MT) or immunostained. Otherwise, tumors were 
resected by surgery before vaccination/docetaxel treat-
ment (n are indicated in corresponding tables).
TIL analysis and in vivo Matrigel plug assay
In this case, 2×106 TC1 cells in 500 µl of Matrigel (4:5) 
were subcutaneously injected into 6 to 8 week- old 
C57BL/6 mice (day 7) following vaccination (day 0) 
and docetaxel treatment (0.83 mg/kg by IP injection on 
day 10) (n=4). On day 12, Matrigel plugs were harvested 
and mechanically disrupted in 1.5 mL Eppendorf tubes 
in the presence of trypsin to study the tumor- infiltrating 
lymphocytes (TIL). Subsequently, cells were centrifuged 
at low speed (200 rpm for 1 min) and the supernatant 
containing the recovered cells was stored, discarding the 
non- disaggregated plug fragments (pellet). From super-
natant, the lymphoid cell number was determined in 
the Neubauer chamber in the presence of trypan blue. 
The Plug infiltrating cells were then phenotyped by flow 
cytometry for the expression of surface molecules (CD8, 
CD4, CD69, CD122, and CD25) and for intracellular 
expression of FoxP3 as previously described.55
Vaccine based on autologous bone-marrow-derived dendritic 
cells
Preparation of BM- DC is adapted from published proto-
cols.56 57 Briefly, the development of dendritic cells (DC) 
from murine bone marrow (BM) progenitor cells was 
performed as previously published.56 57 BM cells were 
cultured overnight in DMEM (Life Technologies) with 
10% FCS (fetal calf serum), 1% penicillin, streptomycin, 
and amphotericin in a Petri dish. On day 1, cells were 
cultured with murine IL4 (500 U/mL;) and murine 
GM- CSF (20 ng/mL; both cytokine from ImmunoTools) 
for 5 days. Non- adherent cells were then re- plated at 
1×105 cells/well in 6- well plates and resuspended at 2×106 
to 5×106 cells/mL in serum- free DMEM and loaded with 
lysates from indicated TC1 (lysate from 1×104 TC1/4×104 
BM- DC/mouse; Gal-3HIGH- vaccine: lysate with TC1- shCtrl; 
Gal-3LOW- vaccine: lysate with TC1- shGal-3 or TC1- shCtrl 
pretreated in vitro for 15 days by LDD) in serum- free 
media for 3 hours at 37°C (5% CO2), and then adjuvants 
(PolyU- PEI (1:15; 20 µg/mL PolyU, Sigma)+CpG (2 ng/
mL; IDT)) was added to allow an overnight maturation of 
BM- DC before mice injection.
Lymphocyte proliferation
For T- cell proliferation assays, 5×105 CFSE- stained murine 
lymph node cells (2.5 µM, 5 min; Sigma) were seeded in 
a 96- well U- bottomed plate. Cells were then stimulated 
for 72 hours with coated anti- CD3 antibody (1 µg/mL, 
145–2 C11 clon, BD Pharmingen) and proliferation 
assessed by CFSE dilution in presence of 5×104 autolo-
gous splenocytes and a variable number of tumor cells as 
indicated. Cells were then stained for CD8 (561093, BD 
Pharmingen) and for CD4 (22 150 046sp, ImmunoTools) 
in staining buffer (PBS 1% FBS, 0.01% sodium azide) for 
30 min on ice, (n=3). Flow cytometry data acquisition was 
performed using a FACSAria (BD Biosciences) and anal-
ysis using the FlowJo software.
Cytotoxic assays
Killing of target cells was measured in lactate dehydro-
genase (LDH)- release assay (Promega). LDH- release was 
measured in an enzymatic assay according to the manu-
facturers' protocol. Death of target cells or % Cytotoxicity 
was calculated as follows (% Cytotoxicity = (Experimental 
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– Effector Spontaneous – Target Spontaneous ×100)/
(Target Maximum – Target Spontaneous)), in which all 
values were normalized by subtraction of the LDH back-
grounds originating from the spontaneous release of 
effector cells. Target cells (TC1 expressing (TC1- WT) 
or silenced for Gal-3 (TC1- shGal-3 or TC1- WT treated 
for 2 weeks with docetaxel (1 nM), respectively) were 
used in this assay. Ten thousand target cells were added 
in a volume of 50 µl well of a 96- well V- bottom microtiter 
plate. Lymphocytes from mice previously immunized with 
BM- DC vaccine (BM- DC pre- loaded with lysate from TC1- 
shGal-3 (Gal-3LOW- vaccine) or TC1–shCtrl (Gal-3HIGH- 
vaccine) as indicated, plus adjuvant (PolyU- PEI (1:15; 
20 µg/mL PolyU)+CpG (2 ng/mL)) as described before. 
A week later, immunized mice received an immune boost 
by injection of corresponding 200,000 TC1- shRNA in 
200 µl of PBS. Then, 5 days after the immune boost injec-
tion, mice were sacrificed and draining axillary, brachial 
and inguinal lymph nodes were recovered and homoge-
nized using BIOFIL cell strainers and a syringe plunger 
on cold RPMI medium containing 10% FBS (v/v). Cells 
were pelleted by centrifugation at 250Xg for 5 min and 
counted using a Neubauer chamber. Different Target:LN 
cells ratios were used as indicated in a final volume of 
100 µL of RPMI complete medium. The microtiter plates 
were centrifuged for 1 min at 250Xg and incubated for 
4 hour at 37°C, 5% CO2. Before harvesting 50 µl/well of 
supernatant, plates were centrifuged again for 4 min at 
250Xg and absorbance was measured at 492 nm by an 
iMARK microplate Reader (BIORAD).
Statistical analysis
Data are presented as mean±SD of at least three sepa-
rate experiments in triplicate. Comparisons between two 
groups were performed by using paired Student’s t- test. 
For the analysis of the differences in tumor incidence, 
the χ2 statistic was applied. The comparison between % 
of tumor- free mice versus time (latency) was performed 
using the Gehan- Breslow- Wilcoxon test, based on a χ2 
distribution. Differences were considered significant 
when p values were less than 0.05 as shown in all figures 
when needed.
RESULTS
Negative regulation of galectin-3 in PCa cell lines 
delays tumor growth and metastasis development in 
immunocompetent mice, but not in athymic nude mice
To understand the apparent contradiction between the 
negative expression of Gal-3 in PCa primary tumors at 
advanced stages of the disease with the demonstrated 
roles of this galectin in the development of metastasis 
and aggressiveness of PCa cells, we designed a murine 
model using TC1 with a controlled Gal-3 expression. 
TRAMP- C mice and TC1 cells are widely used murine 
prostate cancer models that allow the use of syngeneic 
transplants to study immune responses in immunocom-
petent animals.58 59 We had already standardized a model 
based on the subcutaneous injection of TC1 to enable 
us to study various functional aspects of immune cells in 
PCa.55 60 This preclinical model has the advantage that 
tumor cells and hosts share the same genetic background, 
which allows the use of immunocompetent mice, which 
is more representative of what generally occurs in clinics. 
Also, we generated TC1 cells expressing different levels 
of Gal-3 using a lentivirus- derived shRNA expression 
(online supplemental table S1, figure 1A). TC1- shGal-3 
cells showed a stable 95% decrease of the Gal-3 expres-
sion (Gal-3LOW- TC1) compared with the control- shRNA 
transduced cells that express high levels of this lectin 
(TC1- shCtrl, or Gal-3HIGH- TC1) (figure 1A).
We first verified that the high downregulation of Gal-3 
expressed by TC1 cells led to the same and already well- 
characterized roles of this galectin, namely a decrease in 
both the tumorigenesis and metastases. Thus, evaluating 
the tumor growth for several weeks after subcutaneous 
inoculation of TC1- shGal-3 or TC1- shCtrl in C57BL/6 
mice demonstrated a significant delay of 42±32 days in 
the tumor apparition with lower tumorigenicity since 
fewer animals developed tumors when Gal-3 was silenced 
in tumor cells (figure 1B and table 1 No V1 vs No V2, 
*(p<0.01)). Once the tumors appeared, no difference 
in tumor duplication time was observed (online supple-
mental table S2). We then analyzed the level of the Gal-3 
expression in the resulting tumors to verify that the tumor 
growth was not due to recovered Gal-3, and showed that 
Gal-3 was still silenced in TC1- shGal-3- derived tumors 
(Gal-3LOW- tumors) compared with control (online supple-
mental figure S1a,b). Also, results show a high decrease 
in the apparition of metastasis (online supplemental 
table S2). All these results allowed us to validate our TC1 
murine model.
The role of Gal-3 in controlling the function of immune 
cells in a variety of cancers prompted us to analyze tumor 
growth in athymic nude mice to evaluate further if the T 
cell compartment was responsible for these phenotypes. 
Our results demonstrated neither a delay nor a reduction 
of tumorigenicity or metastasis development between 
both tumor conditions (figure 1C, online supplemental 
table S2). Moreover, Gal-3LOW- tumor growth is faster in 
nude mice since duplication times are 11±1 and 7±1 days 
in TC1- shCtrl- derived and TC1- shGal-3- derived tumors, 
respectively (online supplemental table S2, **(p<0.01)). 
We thus hypothesized that Gal-3 expressed by tumor cells 
negatively controlled T cell functions to allow faster PCa 
growth and consequently metastasis development.
Gal-3 expressed by tumor cells controls the tumor growth 
kinetic through its action on lymph node cells
To further verify our hypothesis of Gal-3 controlling 
the immune cell functions, we decided to use precondi-
tioned lymph node cells to evaluate if the delay on tumor 
growth could also be obtained by transferring the immu-
nity induced by Gal-3LOW- TC1 (online supplemental 
figure S2). Briefly, TC1- shCtrl or TC1- shGal-3 cells were 
subcutaneously injected in C57BL/6 immunocompetent 
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Ly5.1 donor mice in order to pre- stimulate immune cells 
by tumor cells expressing different levels of Gal-3. After 5 
days, total donor lymph node cells (LN TC1- shCtrl or LN 
TC1- shGal-3) were harvested and adoptively transferred 
into sublethal irradiated Ly5.2 host mice injected the 
day before with tumor cells expressing wild type levels of 
Gal-3 (TC1- shCtrl). Results confirmed that the absence of 
Gal-3 in TC1 during the pre- stimulation of donor T cells 
(LN TC1- shGal-3) promotes a delay of tumor growth in 
the host mice (figure 1D), without affecting tumor dupli-
cation time significantly (figure 1E), suggesting that the 
latency was not enough to promote a tumor cell selec-
tion by the immune pressure that would then affect the 
duplication time. Also, these results strongly suggested 
that Gal-3 expressed by the tumor cells interferes with 
the establishment of a protective immune response, and 
Gal-3 is thus necessary from the beginning of tumor 
growth.
Gal-3 expressed by tumor cells controls the proliferation of 
activated CD8+ T cells
A protective immune response could be evaluated first by 
the stimulation of T cell to proliferate. We thus analyzed 
the effect of TC1 expressing different levels of Gal-3, 
like other tumor cells, in inhibiting the proliferation 
of immune cells after an in vitro polyclonal activation. 
Briefly, CFSE- labeled lymph node cells were activated 
through a polyclonal manner by an anti- CD3 stimulation 
in the presence of TC1 cells expressing different levels of 
Gal-3 (figure 1F). As expected, the absence of tumor cells 
allows for the efficient proliferation of activated T cells, 
while the presence of Gal-3HIGH- TC1 cells (wild- type or 
control tumor cells, TC1- WT or TC1- shCtrl, respectively) 
inhibits the T cell proliferation of both CD4+ and CD8+ 
T cells. More importantly, the silencing of Gal-3 in tumor 
cells (TC1- shGal-3) allows the recovery of the high prolif-
eration of CD8+ T cells but not of CD4+ T cells (figure 1F). 
Figure 1 Effect of stable tumor Gal-3 silencing in prostate tumor growth and tumor cell infiltration. Determination of the level 
of expression of Gal-3 protein by Western blot (A). Tumor- free survival of TC1- shRNA subcutaneous inoculation in normal (B) 
or athymic nude (C) C57BL/6 mice (N; online supplemental table S2). Tumor expressing a normal level of Gal-3 (TC1- shCtrl) or 
silenced Gal-3 (TC1- shGal-3) were adoptive transferred with TC1- shCtrl preconditioned lymph node cells (LN TC1- shCtrl) or 
with TC1- shGal-3 preconditioned lymph node cells (LN TC1- shGal-3), (Method; online supplemental figure S2; n=12 for each 
condition) (D to F). Two strains of C57BL/6 mice that differed in the gene variant of the CD45 molecule were used. The Ly5.1 
donor strain expresses the CD45.1 variant while the Ly5.2 host strain expresses the CD45.2 variant, which allows the differential 
analysis of the donor and host cells. Tumor growth (TC1- shCtrl) was evaluated in Ly5.2 C57BL/6 mice by caliper- measured 
tumor volume (D). Evaluation of the resulting tumor growth by the time needed to duplicate the tumor volume (E). Proliferation 
assays were performed with lymph node cells isolated from naïve or immunized mice and co- cultured with autologous adherent 
spleen cells in the presence or not of tumor cells expressing different levels of Gal-3 (lymphocytes:tumor cell ratio, 20:1, n=3). 
Non- immunized mice- lymphocytes were assayed for proliferation after polyclonal in vitro stimulation with coated anti- CD3 
antibody (1 µg/mL) for 72 hours, and the proliferation rate was evaluated by dilution of CFSE intensity in the CD8+ or CD4+ T cell 
populations (F). Analysis by flow cytometry of CD3+ tumor infiltrated cells on day 5 post- adoptive transfer (n=5) (G). *p<0.05 
(Student’s t- test). Gal-3,galectin-3; TC1, TRAMP- C1.
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Altogether the results support the hypothesis that Gal-3 
expressed by tumor cells is a critical factor of the delay 
of tumor growth by promoting the activation and prolif-
eration of antitumor CD8+ T cells. This information is 
essential to benefit patients with prostate cancer.
Gal-3 expressed by tumor cells decreases the number of 
tumor-infiltrated T cells without inducing their apoptosis
Not only CD8+ T cells need to proliferate, but they have to 
infiltrate tumors. Since Gal-3 expressed by tumor cells has 
a major impact on early events of lymphocyte activation 
and proliferation occurring in draining lymph nodes, we 
decided to evaluate the impact of such phenomena on 
the number of TIL able to infiltrate tumors expressing 
wild type or down- regulated Gal-3 (Gal-3HIGH- tumors vs 
GAL-3LOW- tumors, respectively). For this and as previously 
described (online supplemental figure S2), we used the 
adoptive transfer of Ly5.1 donor lymph node cells (LN) 
previously preconditioned by TC1- shCtrl or -shGal-3 (LN 
TC1- shCtrl or LN TC1- shGal-3, respectively). In order 
to differentiate host from donor cells, donor LN were 
transferred into Ly5.2 mice hosts -bearing Gal-3HIGH- or 
Gal-3LOW- tumor cells in matrigel plug. On day 6 after 
adoptive transfer, matrigel- plugs allowed us to harvest 
cells from tumor microenvironment to characterize the 
TIL. Results show that the number of donor TIL (CD3+/
Ly5.1+) were significantly increased in plugs containing 
Gal-3LOW- tumor compared with those containing control 
tumor cells (Gal-3HIGH- tumor)(figure 1G), suggesting 
that Gal-3 expressed by the tumor cells is likely an inhib-
itor of TIL infiltration, but not of TIL activation (online 
supplemental figure S3). Moreover, galectins are also 
known to induce apoptosis of T cells, and this effect could 
explain this difference in TIL number. We thus assayed 
for Annexin V/PI labeling and show that Gal-3HIGH- 
tumors do not induce a significant difference in apoptosis 
of CD3+ cells compared with Gal-3LOW- tumors (data not 
shown). Since the tumor has been characterized as an 
immune- privileged microenvironment, we hypothesized 
that Gal-3 expressed by PCa cells is mainly an inhibitor of 
T cell proliferation in lymph nodes and tumor infiltration.
A highly effective antitumor vaccine based on Gal-3LOW–
prostate cancer cell lysate-loaded dendritic cells
To date, immunotherapy has garnered major interest 
in prostate cancer therapy, but all immunotherapies, 
including Sipuleucel- T (the only vaccine authorized by 
the FDA for asymptomatic patients with PCa) and other 
immunotherapies, using anti- checkpoint antibodies, 
had failed to show high efficiency against PCa growth or 
recurrence.12 28 61 We hypothesized that the expression of 
Gal-3 by tumor cells could interfere with T cell behavior 
and thus with vaccine efficiency, and wondered if a ther-
apeutic process similar to Sipuleucel- T, using BM- DC 
loaded with a Gal-3LOW–PCa cell lysate, could be used 
as an effective vaccine to control PCa tumor growth. To 
test our hypothesis, we prepared TC1 lysates from TC1- 
shGal-3 or TC1- shCtrl cells by three successive cycles of 
freezing and thawing to allow for the complete tumor cell 
lysis. Autologous BM- DC were loaded with these lysates 
independently and matured overnight with adjuvants 
prior to being used as a vaccine and before the inocu-
lation of Gal-3LOW- TC1 cells in C57BL/6 naive mice 
(figure 2A). Remarkably, the vaccine based on BM- DC 
loaded with a Gal-3- positive PCa cell lysate (VP1) allowed 
a delay in the growth of Gal-3LOW- tumors compared with 
the unvaccinated mice (No V1), 116±29 days versus 
81±43 days, respectively (figure 2B, table 1: VP1 vs No 
Table 1 Gal-3- silencing in prostate tumor cells by RNA interference or low/non- toxic doses of- docetaxel promotes vaccines' 
effectiveness
Lysate used in 
vaccine Tumor N Tumor incidence (%)
Tumor free- survival 
(days)
No V1 – TC1- shGal-3 14 65* 81±43*
No V2 – TC1- shCtrl 23 92 39±11
No V3 – TC1- shCtrl/DTX 10 80 49±7
VP1 TC1- shCtrl TC1- shGal-3 10 70 116±29
VP2 TC1- shGal-3 TC1- shGal-3 10 0 >275
VP3 TC1- shCtrl /DTX TC1- shGal-3 10 0 >275
VP4 TC1- shCtrl /DTX TC1- shCtrl 10 90 73±35
VP5 TC1- shGal-3 TC1- shCtrl/DTX 10 0 >275
VP5.2 TC1- shGal-3 TC1- shCtrl /DTX
+challenge
5 0 >500
Tumor- bearing mice were vaccinated with BM- DC based vaccine loaded with tumor cells lysate expressing different levels of Gal-3 (Gal-3HIGH- 
vaccine for TC1- shCtrl; or Gal-3LOW- vaccine for TC1- shGal-3 and TC1- shCtrl/DTX) as indicated. The treatments with low and non- toxic doses 
of docetaxel (DTX) correspond to a 1 nM dose in cultured cells during 2 weeks before processing into lysates or 0.83 mg/kg (intraperitoneal 
injection) during 2 weeks, once a week for treated mice.
*p<0.05.
BM, bone marrow; DC, dendritic cells; Gal-3, galectin-3; TC1, TRAMP- C1.
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V1). This VP1 vaccine is similar to the currently used 
tumor lysate- pulsed DC- based approaches. It is unlikely 
that the nature of the lysate might regulate BM- DC prop-
erties as a mechanism to explain the different efficiency 
between Gal-3HIGH and Gal-3LOW vaccine. In fact, the 
analysis of the phenotype and functionality of BM- DC 
(online supplemental figure S4) after incubation with 
different lysates did not reveal any particular modulation 
of these BM- DC to act as professional APC to prime naïve 
T cells. This result suggests that lectin canonical activity 
of Gal-3 cannot explain the resulting vaccine potenti-
ation. However, Gal-3 was also demonstrated to partici-
pate in gene expression and splicing as well,62 63 justifying 
further studies to identify potential Gal-3- target genes 
that could serve as new tumor- associated antigens, and 
to explain the high efficiency of this therapeutic vaccine. 
More interestingly, our results using a vaccine consisting 
in BM- DC loaded with a lysate from Gal-3LOW- TC1 cells 
(VP2), demonstrated complete inhibition of the tumor 
growth of cognate Gal-3LOW –TC1 cells, delay superior to 
275 days (time of the animal euthanasia) compared with 
the no vaccination condition (figure 2B, table 1: VP2 vs 
No V1). Altogether, these results reveal the level of Gal-3 
expression by PCa cells as a key parameter for the success 
of immunotherapy.
Docetaxel treatment promotes the decrease of the Gal-
3 expression in prostate tumor cells and patients with 
metastatic mCRPC as well
Our study went further intending to translate research 
findings rapidly into clinical settings. Since the use of 
interference RNA as therapeutics to control Gal-3 in 
patient’s tumors is not easily feasible in the clinics, we 
examined how the expression of Gal-3 could be decreased 
in patients to promote preconditioning of the tumor 
microenvironment, and thus allowing the success of 
immunotherapy. Our previous study of PCa resistance to 
taxane had revealed docetaxel as an interesting pretreat-
ment to silence Gal-3.64 Docetaxel is well- known to inter-
fere with microtubule depolymerization, promoting cell 
cycle arrest and cell death,65 and it is widely used as a 
chemotherapeutic agent against PCa in patients and thus 
rapidly transferable to a clinical protocol. To verify in our 
TC1 model these preliminary data obtained with human 
PCa cell lines, we first analyzed the survival of TC1 cells at 
different doses of docetaxel and confirmed that TC1 cells 
are sensitive to taxane treatments (EC50=8.10±0.03 nM) 
(figure 3A). Again, when we analyzed the expression of 
Gal-1 and Gal-3 (as the most expressed and immunoreg-
ulatory galectins in PCa29), we found that Gal-3 expres-
sion, among other genes, sharply decreased in TC1 cells 
treated with low doses of docetaxel compared with cells 
under vehicle treatment, both in vitro (figure 3B) and in 
tumors (figure 3C). In contrast, the expression of Gal-1 
was not modified by docetaxel treatment (figure 3B,C). 
More importantly, the docetaxel- mediated negative 
regulation of the Gal-3 expression was also confirmed 
in metastasis samples of patients with chemotherapy- 
treated mCRPC (figure 3D), and it did not significantly 
affect the expression of Gal-1. Since Gal-3 is a well- known 
galectin that could interfere with the immune system,39–43 
and docetaxel- based chemotherapy promotes immuno-
therapy success in PCa patients,51 52 we thus hypothesized 
that docetaxel acts, in part, through Gal-3 silencing in 
prostate tumor cells, which could be helpful for transla-
tional medicine.
In mCRPC patient samples, docetaxel-based chemotherapy 
induces Th1 but not pro-inflammatory gene expression 
profiles
Although cancer chemotherapy leads to leukocyte aplasia 
and has always been considered immunosuppressive, 
numerous clinical and preclinical examples show that 
certain taxane- based chemotherapies may increase the 
efficacy of immunotherapies.45–52 Also, the high level of 
cell death is likely owed to how chemotherapy promotes 
Figure 2 Cellular lysates of Gal-3LOW tumor cells promote 
an efficient autologous dendritic cell- based vaccine against 
Gal-3- silenced prostate tumors. Protocol of vaccination 
uses autologous BM- DC loaded with prostate cancer cell 
lysates expressing a different level of Gal-3 (A). Effect of 
different cellular lysates on the growth of a Gal-3- silenced 
TC1 tumor (TC1- shGal-3), (VP1: lysate from TC1- shCtrl; 
VP2: lysate from TC1- shGal-3; No V1: not vaccinated mice) 


















8 Tiraboschi C, et al. J Immunother Cancer 2020;8:e001535. doi:10.1136/jitc-2020-001535
Open access 
a pro- inflammatory microenvironment that achieves 
additive or synergistic clinical activity with immuno-
therapy. To date, no study confirms the promotion of an 
inflammatory microenvironment, especially in patients 
with PCa. Herein, we thus analyzed the expression of a 
panel of pro- inflammatory genes in metastasis samples of 
patients with mCRPC that have or have not undergone 
chemotherapy protocols. The results in figure 4 clearly 
show that the expression of any of the well- characterized 
pro- inflammatory genes is not modified when analyzed 
in patients with mCRPC treated and untreated with 
docetaxel (figure 4A). To go further in our investigation, 
we also analyzed cytokines/chemokines gene expres-
sion and confirmed that IL-4, IL-10, TGF-β, and IL-17 
genes (as Th2 and Th17 profiles, respectively) showed 
no significant variation (figure 4B). In contrast—and 
more importantly—interleukin 2 and interferon gamma 
(IFNγ), as well as the Perforin genes (characteristic of a 
Th1 profile), significantly increased when patients with 
mCRPC received chemotherapy (figure 4C). These results 
strongly suggest that docetaxel- based chemotherapy 
could favor a Th1 immune response independently 
from pro- inflammatory genes promotion in patients with 
mCRPC, but involving other immune controlling factors 
such as Gal-3.
Gal-3 negative regulation in tumor cells is a critical factor in 
the success of vaccine-based immunotherapy
Previously, we have shown that a Gal-3- silenced PCa cell 
lysate used in a BM- DC- based vaccine interferes with the 
growth of Gal-3LOW tumors (figure 2B). With the goal of 
translational research, we first wondered which precon-
ditioning treatment with docetaxel before vaccination 
could strongly decrease the expression of Gal-3 in tumors 
without affecting the viability of immune cells. We thus 
sought to analyze the survival of immune cells at different 
doses of DTX. Results in figure 5 show that in vivo CD8+ T 
cells (figure 5A) are sensitive to taxane treatments, while 
CD4+ T cells are less sensitive (figure 5B), but no signif-
icant effect on the viability of any type of the T cells was 
observed at doses as low as 0.83 mg/kg, which we defined 
as the LDD to be used in the following experiments. This 
result prompted us to analyze whether this LDD, inducing 
Gal-3 decrease in TC1, enables the same vaccine efficiency 
seen with previously tested RNA interference strategy 
(TC1- shGal-3). For this purpose, we tested if a lysate 
obtained from LDD- pretreated tumor cells (TC1- shCtrl/
DTX) could conclusively be used in a DC- based vaccine 
to control TC1 tumor growth (figure 5C). As shown in 
figure 5D, we observed that such a vaccination (VP4) 
induced a delay in the growth of Gal-3HIGH- tumors but 
failed to fully protect the animals (VP4 vs No V3, figure 5D, 
table 1; 73±35 days vs 49±7 days, respectively). Again, 
BM- DC pulsed with a lysate from LDD- pretreated TC1 
cells (TC1- shCtrl/DTX) or with Gal-3- silenced TC1 cells 
completely inhibited Gal-3LOW- tumor growth (figure 5D, 
table 1; VP3 and VP5, tumors TC1- shGal-3 or TC1- shCtrl/
DTX). This inhibition of tumor growth is similar to the 
antitumoral effect obtained with the TC1- shGal-3 vaccine 
Figure 3 Docetaxel- based chemotherapy induces Gal-3 expression decrease in prostate tumor cells and in patients with 
mCRPC. Dose- dependent cytotoxic effect of docetaxel on TC1 in vitro (A). Docetaxel promotes Gal-3 silencing in TC1 cells 
without affecting Gal-1 expression in vitro (B) and in vivo (C), and in metastatic samples of patients with mCRPC using a 
microarray database (GSE35988) (D).54 *p<0.05. DTX, docetaxel;Gal-1,galectin-1; Gal-3, galectin-3; mCRPC, metastatic and 
castration- resistant PCa; mRNA, messenger RNA; n.s,not significant difference; PCa, prostate cancer; TC1, TRAMP- C1.
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(VP2, figure 2B, table 1), and strongly suggests that the 
main effect of docetaxel is similar to Gal-3 silencing to 
interfere with the Gal-3 expression by tumor cells. Inter-
estingly, a second injection of Gal-3LOW- TC1 cells, as tumor 
challenge, 1 year after the VP5 vaccination still showed 
complete and long- term protection of mice from tumor 
growth (table 1, VP5.2). Altogether, these results show 
that the expression of Gal-3 by PCa tumors is a crucial 
parameter for the success of immunotherapy since Gal-3 
expressed by the tumor is likely the leading cause of pros-
tate cancer immunotherapy failure.
Vaccination with Gal-3LOW–prostate cancer cell lysate loaded 
DC activates cytotoxic CD8+ T cells and reduces the number 
of CD8+-TRegs but not CD4+-TRegs.
To further challenge our hypothesis that the vaccina-
tion success in the absence of Gal-3 was due to the effec-
tive activation of an anticancer immune response, we 
performed tumor infiltration analysis and cytotoxicity 
assays with T cells isolated from immunized mice. Since 
PCa is also characterized by a high level of TReg infil-
tration,5–7 the induction and differentiation of TReg by 
Gal-3 expressed by tumor cells are important parameters 
Figure 4 High- throughput analysis of metastasis transcriptome from metastatic samples of patients with mCRPC, treated 
or not by docetaxel- based chemotherapy. Gene expressions in patients treated with docetaxel (DTX+) or untreated for pro- 
inflammatory genes (A), for cytokines/chemokines gene expressions for Th2 or Th17 (B) or Th1 profiles (C), using microarray 
database (GSE35988).54 IL, interleukin; IFN g, interferon gamma; mCRPC, metastatic and castration- resistant prostate cancer.
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that may impact tumor development. It is well known that 
CD4+CD25+Foxp3+TRegs (CD4TReg) suppress cytotoxic 
CD8+ T cell function. Moreover, CD8+ TRegs strongly 
suppress immune functions in cancer;6 66–69 these cells 
infiltrate tumors and metastatic sites and are associated 
with poor patient survival.68 70 However, no study has eval-
uated their suppressive dependence on Gals.
Their inhibitory function depends on Galectin expres-
sion (eg, essentially Gal-122). Since the Gal-1 expression 
is not modified in TC1- shGal-3 and patients treated 
Figure 5 Low and non- toxic doses of docetaxel decrease Gal-3 expression in prostate tumor cells without affecting T cell 
viability and promote effective vaccine against prostate tumors. Dose- dependent cytotoxic effect of docetaxel on the in vivo 
viability of circulating CD8+ T cells (A) and CD4+ T cells (B). Combinatory protocol of vaccination and docetaxel treatment (C) 
and its effect on mice survival after prostate tumor challenge (D) when the expression of tumor Gal-3 was silenced by stable 
RNA interference (shGal-3)(VP3) or after docetaxel pre- treatment (VP5); or not silenced (VP4) or without vaccination (No V3) (see 
table 1 for details). Analysis of TReg/total T cell ratios of purified TIL from vaccinated mice bearing different Gal-3- expressing 
TC1 tumors, on CD4+ (E) and CD8+ (F) compartment (n=3). Ex vivo cytotoxic assays of splenocytes from vaccinated mice with 
BM- DC loaded with control (white bars) or negatively- regulated Gal-3 (black bars) TC1 lysates against TC1 targets expressing 
different levels of Gal-3. Representative bar graphs at three different Target:Effector ratios for three independent experiments 
are shown (G). BM, bone marrow; DC, dendritic cells; DTX, docetaxel;Gal-3,galectin-3; LDD, low and non- toxic doses of DTX; 
NS,not significant difference; TC1, TRAMP- C1; TIL, tumor- infiltratinglymphocytes.
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with docetaxel, we thus wondered whether Gal-3 could 
have the same function to promote PCa immune toler-
ance. Then, we decided further to study the levels of 
CD4TReg (CD4+CD25+Foxp3+) and CD8TReg (CD8 
+CD122+CD28−) in the prostate tumor microenviron-
ment depending on the level of Gal-3 expression. For 
this, mice bearing Gal-3- expressing or Gal-3- silenced TC1 
tumors (Gal-3HIGH or Gal-3LOW- tumor, respectively) were 
treated or not with LDD (DTX + or −) before vaccination 
to allow preconditioning of tumor microenvironment for 
Gal-3 negative regulation. These mice were then vacci-
nated with BM- DC vaccine loaded with different TC1 lysate 
(from TC1- shGal-3 (Vaccine Gal-3LOW) or TC1- shCtrl 
(Vaccine Gal-3HIGH)). These mice were finally evaluated 
for the infiltrating TReg/total T cells ratios: CD4TReg 
versus total CD4+ T cells or CD8TReg versus total CD8+ 
T cells (figure 5D,E). Despite the slight and insignifi-
cant differences observed in the CD4+ T cell population 
(figure 5E), the ratio between CD8TReg versus total CD8+ 
T cells significantly decreased in Gal-3LOW tumors (Tumor 
Gal-3LOW or LDD- treated tumors (Tumor Gal-3HIGH, 
DTX+)) and mice vaccinated in the absence of Gal-3 
(vaccine Gal-3LOW) (figure 5F). Interestingly, the expres-
sion of Gal-3 should also be weak in the lysate that loaded 
BM- DCs (Vaccine Gal-3LOW) to control tumor growth effec-
tively. Again, vaccination with the lysate from TC1- shCtrl 
(vaccine Gal-3HIGH) only delayed Gal-3LOW- tumor growth 
like the VP1 (table 1) and was unable to decrease the ratio 
of CD8TReg to total CD8+ T cells (figure 5F). In contrast, 
this ratio was significantly decreased with vaccination 
involving lysate from Gal-3LOW- TC1, independently of the 
way of Gal-3 downregulation (RNA interference or LDD 
pretreatment). This result could give some information 
about the cellular mechanism of how such a vaccination 
controlled the growth of Gal-3LOW tumors (VP2 and VP3, 
table 1). Moreover, results confirm that Gal-3 expressed 
by tumor cells plays a key role in allowing high levels of 
CD8TReg that inhibit CD8+ T cell proliferation and func-
tions, empowering tumor immune escape, and conse-
quently PCa growth. More importantly, the success of the 
vaccination is again likely dependent on the Gal-3 nega-
tive status of the tumor. To go further in this functional 
study, we decided to confirm that Gal-3HIGH- tumors affect 
the resultant cytotoxicity of the activated CD8+ T cells. 
For this, we analyzed antitumor cytotoxicity after vacci-
nation using LDH release assays (figure 5G). As results, 
vaccination with BM- DC loaded with a Gal-3HIGH- TC1 
lysate (white bars) promotes the killing of cognate target 
cells (eg, TC1 WT that express normal levels of Gal-3), 
while vaccination with BM- DC loaded with Gal-3LOW- TC1 
lysate (black bars) is much more effective (figure 5G). 
Again, a low level of Gal-3 expression by tumor cells 
defines the increased activity of PCa- specific cytotoxic T 
cells (figure 5G). Altogether, these results support the 
assumption that the negative regulation of Gal-3 in pros-
tate tumor cells is primordial to negatively control the 
number of CD8TReg cells, empowering antitumor CD8+ 
T lymphocyte functions, and finally, promotes the success 
of the vaccination. Our results thus support that Gal-3 is 
a negative immune checkpoint controlling the functions 
of anti- PCa T cells. Interestingly, Gal-3 can be silenced 
easily by a preconditioning treatment with LDD before 
vaccination.
A preconditioning treatment with low and non-toxic doses 
of docetaxel prior to immunotherapy is useful to lead to an 
effective therapeutic vaccine against prostate cancer
We confirmed that the expression of Gal-3 by the tumor 
is one of the key parameters responsible for the failure 
of immunotherapy against PCa. Since LDD interfere with 
the expression of this galectin by prostate tumor cells but 
do not promote cell death (neither tumor cells nor, more 
importantly, immune cells), we decided to test whether 
intraperitoneal injections of LDD before vaccination could 
protect prostate tumor- bearing animals by improving the 
immunotherapy efficiency. For this purpose, we used 
a therapeutic preclinical model that involves a tumor 
resection surgery that mimics prostatectomy usually 
performed in patients. Then, tumor- resected mice were 
treated once a week for 2 weeks with LDD (0.83 mg/kg, 
47- time less compared with the corresponding chemo-
therapeutic doses used in humans, (http://www. fda. gov/ 
cder/ guidance/ index. html)) (figure 6). This precon-
ditioning treatment on day 4 after the tumor resection 
(DR, figure 6) allows negative Gal-3 regulation in the 
remaining tumor cells (likely circulating tumor cells) 
before vaccination with an autologous BM- DC loaded by a 
Gal-3LOW–TC1 lysate (figure 6A, table 2). We finally evalu-
ated the tumor recurrence in those animals. Without any 
vaccination, the results in table 2 show that LDD- induced 
decrease of the Gal-3 expression in tumor cells is insuffi-
cient to control Gal-3HIGH–tumor growth since four from 
seven treated animals showed recurrence of the primary 
tumor growth (No V5 vs No V4, table 2).
Interestingly, LDD- dependent- Gal-3 downregulation 
is sufficient to control metastasis development, as well as 
with Gal-3- silenced tumors (online supplemental figure 
S1c). Besides, vaccination with an autologous BM- DC 
loaded with a Gal-3LOW–TC1 lysate as unique treatment 
was inefficient over a long period of time to completely 
inhibit tumor recurrence after the tumor resection (VT1, 
table 2). More importantly, preconditioning of the tumor 
microenvironment with an LDD treatment right after 
primary tumor resection and before vaccination is essen-
tial to allow immunotherapy to control PCa tumor growth, 
as demonstrated by the absence of tumor recurrence in 
a vast majority of mice (six out of seven) treated with the 
combinatory approach (VT2, table 2). It is thus unlikely 
that Gal-3 expressed by prostate tumor cells directly influ-
ences the metastatic progression or the tumorigenicity of 
PCa cell lines, but more importantly, promotes the suppres-
sive function of the CD8+CD122+CD28 T cells and thus 
the inhibition of antitumor CD8+ T cell cytotoxic activity 
(figure 6B). Finally, chemotherapy based on LDD before 
immunotherapy allows long- term tumor- free outcomes in 
a vast majority of animals. This protocol could be easily 
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transferable to clinical settings to treat all PCa patients as 
soon as they suffered a prostatectomy surgery.
DISCUSSION AND CONCLUSIONS
In this study, we have addressed conflicting findings of the 
role of Gal-3 and its downregulation in primary prostate 
cancer samples. We thus propose Gal-3 as a fundamental 
player in the immune escape, which causes unsuccessful 
vaccine therapy. We first demonstrated that Gal-3 is indi-
rectly responsible for the aggressiveness of prostate cancer 
cells and the metastasis development through its control 
of the immune system. This finding defines Gal-3 as a new 
negative immune checkpoint. Then, we also described 
how docetaxel- based chemotherapy positively affects the 
effectiveness of immunotherapy against PCa. Our results 
show that docetaxel treatment negatively regulates the 
Figure 6 In vivo treatment with low and non- toxic doses of docetaxel prior to a BM- DC vaccination leads to effective 
immunotherapy against PCa, preventing tumor recurrence. Protocol of surgical tumor resection followed by autologous BM- 
DC vaccination, combined or not with docetaxel treatment (0.83 mg/kg, once a week for 2 weeks) prior to vaccination, and 
evaluation of tumor recurrence (A). Two- week treatment with low and nontoxic doses of Docetaxel (LDD) leads to a strong 
decrease in the expression of Gal-3 by tumor cells. When vaccinated with BM- DC loaded with Gal-3Low- tumor cell lysate, 
mice subjected to LDD treatment (right) showed a decrease in the CD8+CD122+CD28-/total CD8+ cells ratio in comparison 
to non- pre- treated mice (left), while the CD4+CD25+FoxP3+ (CD4Treg)/total CD4+ cells ratio remained constant. Moreover, 
metastatic samples of patients with mCRPC treated with this chemotherapy presented increased expression of genes that favor 
an effective cytotoxic response, like perforin and Th1 profile cytokines/chemokines (B). BM, bone marrow; DC, dendritic cells; 
DTX, docetaxel;Gal-3,galectin-3; IL, interleukin; IFN g, interferon gamma;mCRPC, metastatic and castration- resistant PCa;PBS, 
phosphate- buffered saline; PCa, prostate cancer; TC1,TRAMP- C1.
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Gal-3 expression on tumor cells. This biological effect 
results in potentiating the response of the immune system 
to an effective anti- PCa vaccination, positioning Gal-3 as 
a major negative checkpoint of the immune response 
that allows PCa growth and aggressiveness. These results 
match previous bibliographic data suggesting a correla-
tion between the level of the Gal-3 expression by the 
tumor and poor prognosis for patients with PCa.30–32 It is 
exciting that docetaxel still regulates the Gal-3 expression 
also in taxane- resistant PCa cells. This finding allows us to 
propose a functional combinatory therapeutic protocol 
against tumor recurrence for all patients with PCa.
Galectins have already been shown to be proteins 
involved in controlling immune responses in a broad 
range of diseases.44 71 Most reports on cancer have 
focused on Gal-1 and its effect on immune escape, but 
it must be emphasized that different galectin members 
can have different and sometimes opposite effects on 
T cell behavior.20 Gal-3 has been shown strongly 
expressed by PCa primary tumors at the beginning of 
the disease and decreases up to the complete switch- off 
of its expression at advanced stages,29 72 suggesting its 
primary function is to control the priming of the anti-
tumor immune response at the very early stages of the 
disease. We also showed here that this particular galectin 
recovers its expression in metastasis samples of patients 
with mCRPC. However, while we confirmed the correla-
tion between Gal-3 expression and poor prognosis for 
patients with PCa, further studies are needed to under-
stand if Gal-3 recovers its expression in metastases or if 
only Gal-3- positive PCa cells could take out of the primary 
tissue to spread. In this study, we showed for the first time 
that Gal-3 is required for prostate tumor cells to estab-
lish and maintain immune tolerance and that this occurs 
through inducing the deregulation of CD8+ T cell cyto-
toxic responses. Ideally, an effective antitumor vaccine 
requires the correct priming of naive T cells, which, in 
turn, acquires effector functions that enable the eradi-
cation of tumor cells. The data in the literature demon-
strate that cytotoxic CD8+ T cells are the main cell type 
whose presence in infiltrates is associated with better 
prognosis in all types of cancers.73 Our results show for 
the first time that Gal-3 negative regulation in tumor cells 
(accomplished by two different strategies: Docetaxel treat-
ment or a more specific method using lentivirus- drived 
stable RNA interference) allows the efficient activation 
and proliferation of CD8+ cytotoxic T cells by decreasing 
the ratio between CD8+CD122+CD28− TRegs and total 
CD8+ T cells. In agreement, it has been reported that 
Gal-3 in a tumor microenvironment could inhibit CD4 
and CD8 T cell functions.74 More importantly, Gordon- 
Alonso and collaborators showed that Gal-3 secreted by 
tumor cells sequesters the IFNγ in the stroma;43 the use 
of various Gal-3 inhibitors allow this cytokine to induce 
a correct Th1 polarization and the cytotoxic activity of 
T cells in different tumor models and patients as well. 
Our high- throughput analysis of gene expression shows 
that docetaxel chemotherapy decreases Gal-3 expression 
in mCRPC patient samples and promotes the expression 
of Th1 and cytotoxic genes such as perforin. Altogether, 
these data support tumor- derived Gal-3 as a critical 
negative checkpoint of the anti- PCa immune response, 
promoting the tumor- infiltration of a high number of 
CD8+CD122+CD28− regulatory T cells that finally inhibits 
the cytotoxic functions of antitumor CD8+ T cells.
Recently, it has been observed that Taxol derivates- 
based chemotherapy has a positive influence on cancer 
immunotherapy. In fact, some reports revealed that 
docetaxel treatment promotes the survival of activated 
T cells in colons,46 Lewis lung,45 and metastatic breast49 
cancers. We found that low and non- toxic doses of this 
taxane (a 47- times lower dose than that currently used 
in chemotherapeutic protocols) neither promote lymph-
openia nor induce the death of tumor cells (figures 5A,B 
and 3A, respectively). However, treatment with these LDD 
strongly decreases the expression of Gal-3 by tumor cells, 
among other genes, both in vitro and in vivo, leading to 
an active antitumor CD8+ T cell expansion with cytotoxic 
functions and tumor infiltration. This finding may have a 
high impact on the development of vaccine- based immu-
notherapies for PCa. Given the limited success of the 
only immunotherapy approved for patients with mCRPC 
(Sipuleucel- T; overall survival of 4.1 months12) and the 
absence of a response of all other immunotherapies 
against PCa, our results suggest that the Gal-3 expression 
by tumor cells or circulating prostate tumor cells could be 
Table 2 Combination of low and non- toxic doses of docetaxel and therapeutic immunotherapy leads to the inhibition of 
prostate tumor recurrence and metastasis





No V4 – Gal-3HIGH – 7/8 7/8 Steatosis
No V5 – Gal-3HIGH + 4/7 1/7 Splenomegaly+steatosis
VT1 Gal-3LOW Gal-3HIGH – 4/7 4/7 Increased lymph node size
VT2 Gal-3LOW Gal-3HIGH + 1/7 0/7 Increased lymph node size
Gal-3HIGH tumor- bearing mice underwent tumor resection surgery 4 days before receiving or not intraperitoneal injections of low and non- toxic 
doses of docetaxel (LDD: 0.83 mg/kg during 2 weeks, once a week), and then all tumor- resected mice were vaccinated with BM- DC- based 
vaccine loaded by Gal-3LOW- tumor cells lysate (TC1- shGal-3) or not as indicated. Observations were made after the sacrifice of the animals.
BM, bone marrow; DC, dendritic cells; Gal-3, galectin-3; LDD, low and non- toxic doses of docetaxel.
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one of the reasons for the ineffectiveness of these strate-
gies for treating patients with PCa.
Our results suggest that the efficiency of a DC- based 
vaccine against PCa strongly depends on the Gal-3 status 
of the tumor. Since primary tumors in advanced PCa are 
mostly Gal-3 downregulated, it is conceivable that these 
phases of the disease are favorable to immunotherapy. 
However, the decreased expression of Gal-3 was only 
identified in primary prostate tumors but not in mCRPC 
samples, and no data exist on the level of expression of 
this galectin in corresponding circulating tumor cells 
(CTC), the remaining cells after tumor resection or pros-
tatectomy. It is likely that the expression of Gal-3 might 
be controlled before patients with PCa undergo immuno-
therapy protocols. Unfortunately, the reduced number of 
CTC in patients with PCa does not easily allow this kind 
of pre- analysis.75 Gal-3 could then be used not only as a 
bad prognosis for patients with PCa but also as a marker 
of immunotherapy resistance. Finally, the examination of 
the few anticancer clinical trials involving galectins shows 
Gal-3 as a critical target,28 but none of the ongoing trials 
already combined Gal-3 inhibitors before therapeutic 
vaccination. We thus propose that patients should take 
advantage of pretreatment with low and non- toxic doses 
of docetaxel to decrease the Gal-3 expression in the 
remaining tumor cells prior to vaccination to improve 
immunotherapy success.
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Table S3: Antibodies used to determine galectins, intra- and extra-cellular- proteins 
and housekeeping gene.  
 
Protein Antibody catalog #  Dilution 
β-tubulin H-235, Santa Cruz 1:500 
Galectin-3 H-160, Santa Cruz 1:400 
Goat Anti-Rabbit 
IgG H&L -HRP 
conjugated 
Ab97051, Abcam 1:10,000 
α CD8alfa-APC 561093, BD Pharmingen 1:500 
α CD69-PE 553237, BD Pharmingen 1:100 
α CD107a-PE 558661, BD Pharmingen 1:100 
α CD45.1-PE 553776, BD Pharmingen 1:100 
α CD69-PeCy7 552879, BD Pharmingen 1:100 
α CD4-APC 22150046sp, ImmunoTools 1:500 
α CD122-FITC 11-1222-82, Invitrogen 1:200 
α FoxP3-PE 560414, BD Bioscience 1:100 
α CD25-FITC M5912, Ligands Biotech 1:200 
α CD80-PE 12-0807-81, Invitrogen 1:200 
α MHCII-PerCP 46-5321-80, Invitrogen 1:500 
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14 92 39±11 7±2 80% 
TC1-shGal-3 
/C57BL6 WT 
23 65* 81±43* 6±1 25% 
TC1-shCtrl 
/ nude 
7 100 27±5 11±1 100% 
TC1-shGal-3 
/ nude 
8 100 27±2 7±1** 100% 
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